Piper Sandler analyst Do Kim raised the firm’s price target on Ionis Pharmaceuticals to $62 from $60 and keeps an Overweight rating on the shares. Eplontersen, the company’s investigational medicine to treat transthyretin amyloidosis, continues to be a key driver of share value, Kim tells investors. FDA acceptance of eplontersen is expected in Q1. The company is expected to reveal data from the drug’s NEURO study in mid-2023 and this should be a catalyst, the analyst said. Kim adds olezarsen should be Ionis’ next commercial product and Phase 3 data is expected in the second half of this year.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IONS:
- Royalty, Ionis enter into royalty agreement for up to $1.1B
- Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis’ genetic medicines and commercial readiness
- Ionis Pharmaceuticals, Royalty Pharma enter $1.1B royalty agreement
- Ionis 2023 revenue estimate raised at Guggenheim
- Ionis assumed with Equal Weight from Overweight at Morgan Stanley